<DOC>
	<DOCNO>NCT03024996</DOCNO>
	<brief_summary>This Phase III , multicenter , randomize , placebo-controlled , double-blind study evaluate efficacy safety atezolizumab versus placebo participant RCC high risk disease recurrence follow nephrectomy .</brief_summary>
	<brief_title>A Study Atezolizumab Adjuvant Therapy Participants With Renal Cell Carcinoma ( RCC ) High Risk Developing Metastasis Following Nephrectomy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>ECOG performance status less equal ( &lt; /= ) 1 Pathologically confirm RCC component either clear cell histology sarcomatoid histology previously treat adjuvant neoadjuvant set classified high risk RCC recurrence Radical partial nephrectomy lymphadenectomy select participant Absence residual disease absence metastasis , confirm negative baseline compute tomography ( CT ) pelvis , abdomen , chest 4 week prior randomization . Absence brain metastasis , confirm negative CT contrast magnetic resonance imaging ( MRI ) scan brain , 4 week prior randomization . Applicable metastasectomy participant Full recovery nephrectomy metastasectomy within 12 week randomization follow surgery Bilateral synchronous tumor inheritable form RCC include von HippelLindau Any approve anticancer therapy , include chemotherapy hormonal therapy , within 3 week prior initiation study treatment Treatment investigational agent participation another clinical study therapeutic intent within 28 day five halflives investigational agent , whichever longer , prior enrollment Malignancies RCC within 5 year prior Cycle 1 , Day 1 Participants prior allogeneic stem cell solid organ transplantation History idiopathic pulmonary fibrosis ( include pneumonitis ) , druginduced pneumonitis , organize pneumonia ( i.e. , bronchiolitis obliterans , cryptogenic organize pneumonia ) , evidence active pneumonitis screen chest CT scan Positive test HIV Participants active hepatitis B hepatitis C Active tuberculosis Severe infection within 4 week prior randomization include limited hospitalization complication infection , bacteremia , severe pneumonia Major surgical procedure within 4 week prior randomization anticipation need major surgical procedure course study diagnosis Administration live , attenuate vaccine within 4 week Cycle 1 , Day 1 Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render participant high risk treatment complication Prior treatment cluster differentiation ( CD ) 137 agonist , anticytotoxic Tlymphocyteassociated protein4 ( antiCTLA4 ) , antiprogrammed death1 ( antiPD−1 ) , antiprogrammed deathligand 1 ( antiPDL1 ) therapeutic antibody pathwaytargeting agent Treatment systemic immunostimulatory agent ( include limit interferon interleukin2 ) within 6 week five halflives drug , whichever short , prior randomization Treatment systemic immunosuppressive medication ( include limited corticosteroid , cyclophosphamide , azathioprine , methotrexate , thalidomide , anti−tumor necrosis factor agent ) within 2 week prior randomization anticipate need systemic immunosuppressive medication study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>